CMTM6

Across TCGA pan-cancer cohorts, CMTM6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CMTM6 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CMTM6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CMTM6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where CMTM6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.742	0.096	.024	13	view →
PDAC	DFS	Median	All	0.299	0.492	.014	5	view →
HNSC	OS	Quartile	IV	0.904	0.595	.019	4	view →
CCRCC	OS	Median	All	0.554	1.000	.031	3	view →
LSCC	DFS	Median	All	0.624	0.792	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CMTM6–LUAD (DFS)

Open the LUAD breakdown →